Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients

Kazuo Koyanagi, Takuji Mori, Steven J. O'Day, Steve R. Martinez, He Jing Wang, Dave S B Hoon

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Although previous studies have separately shown the utility of circulating tumor cells (CTC) or cell-free tumor-related DNA in blood of cancer patients, there has been no investigation of their association and/or the prognostic value of combining these assessments. To date, the true source of tumor-related DNA in serum remains unknown. We hypothesized that CTC is a possible origin of serum tumor-related methylated DNA and their combination can predict disease outcome. To test this hypothesis, we obtained matched pairs of peripheral blood lymphocytes and serum specimens simultaneously from 50 American Joint Committee on Cancer stage IV melanoma patients before administration of biochemotherapy. Peripheral blood leukocytes were analyzed for three mRNA markers of CTC: MART-1, GalNAc-T, and MAGE-A3. Sera were analyzed for two methylated DNA markers: RASSF1A and RAR-β2. CTC were detected in 13 of 15 (86%) patients with serum tumor-related methylated DNA and only in 13 of 35 (37%) patients without methylated DNA (P = 0.001). The number of CTC markers detected significantly correlated with methylated DNA (P = 0.008). CTC and methylated DNA were significantly correlated with biochemotherapy-treated patients' outcome. Patients with both CTC and methylated DNA showed significantly poorer response to biochemotherapy (P = 0.02) and worse time to progression and overall survival (P = 0.009 and 0.02, respectively). The correlation between CTC and serum tumor-related methylated DNA and the significant effect of this correlation on disease outcome indicate that a composite molecular assessment in blood may be a useful determinant of disease status and efficacy of systemic therapy for melanoma.

Original languageEnglish (US)
Pages (from-to)6111-6117
Number of pages7
JournalCancer Research
Volume66
Issue number12
DOIs
StatePublished - Jun 15 2006
Externally publishedYes

Fingerprint

Circulating Neoplastic Cells
Melanoma
DNA
Serum
Neoplasms
Tumor Biomarkers
Genetic Markers
Leukocytes
Lymphocytes
Messenger RNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. / Koyanagi, Kazuo; Mori, Takuji; O'Day, Steven J.; Martinez, Steve R.; Wang, He Jing; Hoon, Dave S B.

In: Cancer Research, Vol. 66, No. 12, 15.06.2006, p. 6111-6117.

Research output: Contribution to journalArticle

Koyanagi, Kazuo ; Mori, Takuji ; O'Day, Steven J. ; Martinez, Steve R. ; Wang, He Jing ; Hoon, Dave S B. / Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. In: Cancer Research. 2006 ; Vol. 66, No. 12. pp. 6111-6117.
@article{71df5456e92e41bab4e25ed51257567e,
title = "Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients",
abstract = "Although previous studies have separately shown the utility of circulating tumor cells (CTC) or cell-free tumor-related DNA in blood of cancer patients, there has been no investigation of their association and/or the prognostic value of combining these assessments. To date, the true source of tumor-related DNA in serum remains unknown. We hypothesized that CTC is a possible origin of serum tumor-related methylated DNA and their combination can predict disease outcome. To test this hypothesis, we obtained matched pairs of peripheral blood lymphocytes and serum specimens simultaneously from 50 American Joint Committee on Cancer stage IV melanoma patients before administration of biochemotherapy. Peripheral blood leukocytes were analyzed for three mRNA markers of CTC: MART-1, GalNAc-T, and MAGE-A3. Sera were analyzed for two methylated DNA markers: RASSF1A and RAR-β2. CTC were detected in 13 of 15 (86{\%}) patients with serum tumor-related methylated DNA and only in 13 of 35 (37{\%}) patients without methylated DNA (P = 0.001). The number of CTC markers detected significantly correlated with methylated DNA (P = 0.008). CTC and methylated DNA were significantly correlated with biochemotherapy-treated patients' outcome. Patients with both CTC and methylated DNA showed significantly poorer response to biochemotherapy (P = 0.02) and worse time to progression and overall survival (P = 0.009 and 0.02, respectively). The correlation between CTC and serum tumor-related methylated DNA and the significant effect of this correlation on disease outcome indicate that a composite molecular assessment in blood may be a useful determinant of disease status and efficacy of systemic therapy for melanoma.",
author = "Kazuo Koyanagi and Takuji Mori and O'Day, {Steven J.} and Martinez, {Steve R.} and Wang, {He Jing} and Hoon, {Dave S B}",
year = "2006",
month = "6",
day = "15",
doi = "10.1158/0008-5472.CAN-05-4198",
language = "English (US)",
volume = "66",
pages = "6111--6117",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients

AU - Koyanagi, Kazuo

AU - Mori, Takuji

AU - O'Day, Steven J.

AU - Martinez, Steve R.

AU - Wang, He Jing

AU - Hoon, Dave S B

PY - 2006/6/15

Y1 - 2006/6/15

N2 - Although previous studies have separately shown the utility of circulating tumor cells (CTC) or cell-free tumor-related DNA in blood of cancer patients, there has been no investigation of their association and/or the prognostic value of combining these assessments. To date, the true source of tumor-related DNA in serum remains unknown. We hypothesized that CTC is a possible origin of serum tumor-related methylated DNA and their combination can predict disease outcome. To test this hypothesis, we obtained matched pairs of peripheral blood lymphocytes and serum specimens simultaneously from 50 American Joint Committee on Cancer stage IV melanoma patients before administration of biochemotherapy. Peripheral blood leukocytes were analyzed for three mRNA markers of CTC: MART-1, GalNAc-T, and MAGE-A3. Sera were analyzed for two methylated DNA markers: RASSF1A and RAR-β2. CTC were detected in 13 of 15 (86%) patients with serum tumor-related methylated DNA and only in 13 of 35 (37%) patients without methylated DNA (P = 0.001). The number of CTC markers detected significantly correlated with methylated DNA (P = 0.008). CTC and methylated DNA were significantly correlated with biochemotherapy-treated patients' outcome. Patients with both CTC and methylated DNA showed significantly poorer response to biochemotherapy (P = 0.02) and worse time to progression and overall survival (P = 0.009 and 0.02, respectively). The correlation between CTC and serum tumor-related methylated DNA and the significant effect of this correlation on disease outcome indicate that a composite molecular assessment in blood may be a useful determinant of disease status and efficacy of systemic therapy for melanoma.

AB - Although previous studies have separately shown the utility of circulating tumor cells (CTC) or cell-free tumor-related DNA in blood of cancer patients, there has been no investigation of their association and/or the prognostic value of combining these assessments. To date, the true source of tumor-related DNA in serum remains unknown. We hypothesized that CTC is a possible origin of serum tumor-related methylated DNA and their combination can predict disease outcome. To test this hypothesis, we obtained matched pairs of peripheral blood lymphocytes and serum specimens simultaneously from 50 American Joint Committee on Cancer stage IV melanoma patients before administration of biochemotherapy. Peripheral blood leukocytes were analyzed for three mRNA markers of CTC: MART-1, GalNAc-T, and MAGE-A3. Sera were analyzed for two methylated DNA markers: RASSF1A and RAR-β2. CTC were detected in 13 of 15 (86%) patients with serum tumor-related methylated DNA and only in 13 of 35 (37%) patients without methylated DNA (P = 0.001). The number of CTC markers detected significantly correlated with methylated DNA (P = 0.008). CTC and methylated DNA were significantly correlated with biochemotherapy-treated patients' outcome. Patients with both CTC and methylated DNA showed significantly poorer response to biochemotherapy (P = 0.02) and worse time to progression and overall survival (P = 0.009 and 0.02, respectively). The correlation between CTC and serum tumor-related methylated DNA and the significant effect of this correlation on disease outcome indicate that a composite molecular assessment in blood may be a useful determinant of disease status and efficacy of systemic therapy for melanoma.

UR - http://www.scopus.com/inward/record.url?scp=33745700207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745700207&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-4198

DO - 10.1158/0008-5472.CAN-05-4198

M3 - Article

C2 - 16778184

AN - SCOPUS:33745700207

VL - 66

SP - 6111

EP - 6117

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 12

ER -